Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

ORIGINAL_headquarters_ingelheim
Employees at Boehringer Ingelheim

Empowering all employees

Boehringer Ingelheim has been awarded as a Global Top Employer. Sven Sommerlatte, Global Head of Human Resources and Antonella Francabandera, Global Head of Talent Acquisition & People Growth explain what drives our corporate innovation culture.

EFPIA disclosure
Transparency
Corporate Profile

EFPIA disclosure

Disclosure of Boehringer Ingelheim affiliates in countries with EFPIA member associations
Read more
Our Employees: Our Greatest Asset
HR
Corporate Profile

Our Employees: Our Greatest Asset

The employees of Boehringer Ingelheim form the core of our corporate culture as a family-owned company that lives out its responsibility and builds on mutual respect and fairness.
Read more
Board of Managing Directors
ORIGINAL_headquarters_ingelheim3.jpg
Corporate Profile

Board of Managing Directors

As a family-owned company Boehringer Ingelheim is governed by the Board of Managing Directors composed of five members. Read more about their respective responsibilities.
Read more
Read more
card_financial_highlights
About us

Financial Highlights 2020

Net sales, R&D expenditures, Operating Income and Personnel Capacity: Boehringer Ingelheim grows and invests in 2020
Read more
An adult wearing protective equipment looks at a test tube

Annual Report 2021: Tomorrow

Tomorrow holds great opportunities for more progress, more sustainability, and better health. Read inspiring stories on our understanding of a healthier future in our annual report.